Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of SB-497115 in chronic hepatitis C-related thrombocytopenia
2004-001469-16Phase 2Terminated
- Sponsor
- GSK
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eltrombopag in Thrombocytopenia and hepatitis C virus infection (4 arms), sponsored by GSK. Primary endpoint: Primary efficacy endpoint. Started Feb 2005; status: terminated.
02
Drugs
eltrombopag
03
Conditions
Thrombocytopeniahepatitis C virus infection
Beyond the preview
Go deeper on 2004-001469-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001469-16.